Equities research analysts expect Elanco Animal Health (NYSE:ELAN) to post $564.49 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Elanco Animal Health’s earnings. The highest sales estimate is $630.10 million and the lowest is $519.36 million. Elanco Animal Health posted sales of $781.60 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 27.8%. The company is expected to report its next quarterly earnings results on Tuesday, August 11th.
According to Zacks, analysts expect that Elanco Animal Health will report full-year sales of $2.74 billion for the current financial year, with estimates ranging from $2.62 billion to $2.79 billion. For the next financial year, analysts anticipate that the company will post sales of $2.95 billion, with estimates ranging from $2.87 billion to $3.05 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Elanco Animal Health.
Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.13 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.24 by ($0.11). Elanco Animal Health had a negative net margin of 0.42% and a positive return on equity of 6.10%. The firm had revenue of $657.70 million for the quarter, compared to analysts’ expectations of $720.19 million. During the same period in the prior year, the business posted $0.25 earnings per share. The business’s quarterly revenue was down 10.0% on a year-over-year basis.
Several hedge funds have recently modified their holdings of ELAN. Amundi Pioneer Asset Management Inc. boosted its position in shares of Elanco Animal Health by 49.0% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 16,315,711 shares of the company’s stock valued at $480,499,000 after purchasing an additional 5,364,089 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Elanco Animal Health by 55.9% during the first quarter. BNP Paribas Arbitrage SA now owns 164,258 shares of the company’s stock valued at $3,678,000 after purchasing an additional 58,887 shares in the last quarter. Public Sector Pension Investment Board bought a new stake in shares of Elanco Animal Health during the first quarter valued at approximately $14,789,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its position in shares of Elanco Animal Health by 72.3% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 83,500 shares of the company’s stock valued at $2,459,000 after purchasing an additional 35,029 shares in the last quarter. Finally, M&T Bank Corp boosted its position in shares of Elanco Animal Health by 55.9% during the first quarter. M&T Bank Corp now owns 14,683 shares of the company’s stock valued at $329,000 after purchasing an additional 5,263 shares in the last quarter.
ELAN traded up $0.02 on Friday, hitting $21.21. 2,467,336 shares of the company were exchanged, compared to its average volume of 4,161,090. The firm has a fifty day simple moving average of $21.33 and a two-hundred day simple moving average of $25.14. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.97 and a current ratio of 4.41. Elanco Animal Health has a 12 month low of $15.17 and a 12 month high of $35.23. The stock has a market capitalization of $8.46 billion, a PE ratio of -1,060.50, a price-to-earnings-growth ratio of 2.50 and a beta of 0.87.
Elanco Animal Health Company Profile
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Featured Story: Outperform Rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.